These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 16494249)

  • 1. A simulation study comparing different experimental designs for estimating uptake and elimination rates.
    Bell BR; Bailer AJ; Wright SE
    Environ Toxicol Chem; 2006 Jan; 25(1):248-52. PubMed ID: 16494249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estimation of pharmacokinetic parameters by orthogonal regression: comparison of four algorithms.
    Tod M; Aouimer A; Petitjean O
    Comput Methods Programs Biomed; 2002 Jan; 67(1):13-26. PubMed ID: 11750944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of robust criteria for D-optimal designs.
    Foo LK; McGree J; Eccleston J; Duffull S
    J Biopharm Stat; 2012; 22(6):1193-205. PubMed ID: 23075017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal population designs for PK models with serial sampling.
    Gagnon R; Leonov S
    J Biopharm Stat; 2005; 15(1):143-63. PubMed ID: 15702610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A simulation study of methods for constructing confidence intervals for bioaccumulation factors.
    Wheeler MW; Bailer AJ
    Environ Toxicol Chem; 2003 Apr; 22(4):921-7. PubMed ID: 12685730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An evaluation of population D-optimal designs via pharmacokinetic simulations.
    Hooker AC; Foracchia M; Dodds MG; Vicini P
    Ann Biomed Eng; 2003 Jan; 31(1):98-111. PubMed ID: 12572660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Some considerations on the design of population pharmacokinetic studies.
    Duffull S; Waterhouse T; Eccleston J
    J Pharmacokinet Pharmacodyn; 2005 Aug; 32(3-4):441-57. PubMed ID: 16284917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Parametric and nonparametric population methods: their comparative performance in analysing a clinical dataset and two Monte Carlo simulation studies.
    Bustad A; Terziivanov D; Leary R; Port R; Schumitzky A; Jelliffe R
    Clin Pharmacokinet; 2006; 45(4):365-83. PubMed ID: 16584284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A pragmatic approach to the design of population pharmacokinetic studies.
    Roy A; Ette EI
    AAPS J; 2005 Oct; 7(2):E408-20. PubMed ID: 16353920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal design criteria for discrimination and estimation in nonlinear models.
    Waterhouse TH; Eccleston JA; Duffull SB
    J Biopharm Stat; 2009; 19(2):386-402. PubMed ID: 19212887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal design for multiresponse pharmacokinetic-pharmacodynamic models - dealing with unbalanced designs.
    Ogungbenro K; Gueorguieva I; Majid O; Graham G; Aarons L
    J Pharmacokinet Pharmacodyn; 2007 Jun; 34(3):313-31. PubMed ID: 17285361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal initial state for fast parameter estimation in nonlinear dynamical systems.
    Li Q; Jauberthie C; Denis-Vidal L; Cherfi Z
    Comput Methods Programs Biomed; 2019 Apr; 171():109-117. PubMed ID: 27526628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Importance of Temporal Design: How Do Measurement Intervals Affect the Accuracy and Efficiency of Parameter Estimates in Longitudinal Research?
    Timmons AC; Preacher KJ
    Multivariate Behav Res; 2015; 50(1):41-55. PubMed ID: 26609742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simultaneous optimal experimental design for in vitro binding parameter estimation.
    Ernest CS; Karlsson MO; Hooker AC
    J Pharmacokinet Pharmacodyn; 2013 Oct; 40(5):573-85. PubMed ID: 23943088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selecting the best design for nonstandard toxicology experiments.
    Webb JM; Smucker BJ; Bailer AJ
    Environ Toxicol Chem; 2014 Oct; 33(10):2399-406. PubMed ID: 24943385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimal statistical design for toxicokinetic studies.
    Beatty DA; Piegorsch WW
    Stat Methods Med Res; 1997 Dec; 6(4):359-76. PubMed ID: 9447654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An experimental design tool to optimize inference precision in data-driven mathematical models of bacterial infections
    Vlazaki M; Price DJ; Restif O
    J R Soc Interface; 2020 Dec; 17(173):20200717. PubMed ID: 33323052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and analysis of in vitro antitumor pharmacodynamic studies.
    Kalns JE; Millenbaugh NJ; Wientjes MG; Au JL
    Cancer Res; 1995 Nov; 55(22):5315-22. PubMed ID: 7585594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Experimental design and efficient parameter estimation in preclinical pharmacokinetic studies.
    Ette EI; Howie CA; Kelman AW; Whiting B
    Pharm Res; 1995 May; 12(5):729-37. PubMed ID: 7479560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An experimental design strategy for quantitating complex pharmacokinetic models: enterohepatic circulation with time-varying gallbladder emptying as an example.
    Wang YM; Reuning RH
    Pharm Res; 1992 Feb; 9(2):169-77. PubMed ID: 1553336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.